<DOC>
	<DOCNO>NCT01911325</DOCNO>
	<brief_summary>This multi-center , open-label Phase Ib dose escalation part follow randomized double-blinded placebo control Phase II part . The Phase Ib part determine Maximum Tolerated Dose ( MTD ) /Recommended Phase II Dose ( RP2D ) buparlisib combination docetaxel . Subsequently MTD/RP2D investigate Phase II randomize trial patient advance metastatic squamous NSCLC .</brief_summary>
	<brief_title>Phase II Study Buparlisib + Docetaxel Advanced Metastatic Squamous Non-small Cell Lung Cancer ( NSCLC ) Patients</brief_title>
	<detailed_description>Based overall review safety preliminary efficacy data do 01-Dec-2014 show marginal anti-tumor activity newly emerge treatment option , decision take stop development combination patient advance metastatic squamous NSCLC Phase II study conduct .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Patient adult ≥ 18 year old time inform consent Patient histologically and/or cytologically confirm diagnosis squamous NSCLC . Diagnosis mixed squamous nonsquamous adenosquamous NSCLC acceptable enrollment . Patient receive one prior approve regimen platinumbased chemotherapy ( exclude docetaxelcontaining regimen ) advance metastatic ( Stage IIIb Stage IV ) squamous NSCLC , follow disease progression . A drug provide maintenance therapy follow cytotoxic chemotherapy consider part regimen . Note : Patients receive paclitaxel therapy eligible trial . •Patient adequate tumor tissue ( either archival new tumor biopsy ) analysis PI3Krelated biomarkers . Enrollment Phase II part study contingent central laboratory confirm receipt adequate amount tissue include sufficient DNA analysis . •Patient measurable nonmeasurable disease accord RECIST version 1.1 criterion . Phase II : Patient must least one measurable lesion per RECIST criterion . Patient ECOG performance status ≤ 1 Patient adequate bone marrow organ function Patient receive previous treatment PI3K AKT inhibitor Patient symptomatic Central Nervous System ( CNS ) metastases Patients asymptomatic CNS metastasis may participate trial . The patient must complete prior local treatment , , CNS metastases ≥ 28 day prior start study treatment ( include radiotherapy and/or surgery , ≥ 14 day stereotactic radiosurgery ) . Patient score ≥ 12 PHQ9 questionnaire . Patient selects response `` 1 , 2 3 '' question number 9 PHQ9 questionnaire regard potential suicidal thought ideation ( independent total score PHQ9 ) . Patient GAD7 mood scale score ≥ 15 . Patient medically document history active major depressive episode , bipolar disorder ( I II ) , obsessivecompulsive disorder , schizophrenia , history suicidal attempt ideation , homicidal ideation patient active severe personality disorder . Patient ≥ CTCAE grade 3 anxiety</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Squamous non-small cell lung cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Buparlisib</keyword>
	<keyword>BKM120</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Stage IIIb</keyword>
	<keyword>Stage IV</keyword>
	<keyword>PI3K inhibitor</keyword>
</DOC>